IL6 and posterior cortical atrophy: Our study demonstrated for the first time that IL6 levels can help to classify PCa patients whose frailty syndrome severity increased during ADT treatment, i.e., the area under the ROC curve obtained for IL-6 (0.67) indicates a moderate accuracy in the predictive value of this biomarker for frailty.